Next-Generation Neutral Sphingomyelinase-2 Inhibitors with Improved Solubility, Pharmacokinetics, and Efficacy in a Tau Propagation Model
Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 26452-26468
DOI: 10.1021/acs.jmedchem.6c02429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.10.2026. Verfasst von Arina Ranjit und 14 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, Maryland21205, United States. Hauptthemen laut MEDLINE: Sphingomyelin Phosphodiesterase, Enzyme Inhibitors. Die Arbeit nennt 54 Literaturangaben. Gefördert von: NCI NIH HHS, NIA NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Neutral sphingomyelinase 2 (nSMase2) is a promising therapeutic target implicated in disease progression. We previously identified PDDC [phenyl (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)-pyrrolidin-3-yl) carbamate], a sub-micromolar nSMase2 inhibitor with favorable efficacy and pharmacokinetics in mice. However, poor aqueous solubility and suboptimal pharmacokinetics in higher species limited its translational potential. To overcome these limitations, we introduced hydroxy groups on the southern phenyl ring and simultaneously optimized the northern phenyl-carbamate moiety. Compound 8a [(phenyl (R)-(1-(3-(4-hydroxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl) carbamate] exhibited comparable potency and pharmacokinetics to PDDC but remained poorly soluble. To address this, we derivatized the hydroxy group with hydrophilic phosphate promoeities, generating soluble analogues of 8a. Of these, 12a demonstrated excellent aqueous solubility and efficiently released 8a, resulting in improved pharmacokinetics, target engagement, and efficacy in mice. In dogs, oral dosing of 12a resulted in the release of 8a, with the released 8a exhibiting 47% absolute oral bioavailability, supporting its translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, Maryland21205, United States.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland21205, United States.
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland21205, United States.
- Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland21205, United States.
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland21205, United States.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland21205, United States.
ORCID-Profile: Ruoning Zhang, Yu Su, Peter Pietri, Taeyoon Jung, Barbara S Slusher, Rana Rais
Förderung
- NCI NIH HHS
- NIA NIH HHS
- National Cancer Institute
- National Institute on Aging
Zitieren
APA
Ranjit, A., Tenora, L., Huang, M., Wu, Y., Thomas, A. G., Lee, C. B., Alt, J., Zhang, R., Maragakis, R. M., Zheng, Y., Su, Y., Pietri, P., Jung, T., Slusher, B. S., & Rais, R. (2026). Next-Generation Neutral Sphingomyelinase-2 Inhibitors with Improved Solubility, Pharmacokinetics, and Efficacy in a Tau Propagation Model. Journal of Medicinal Chemistry, 69(21), 26452-26468. https://doi.org/10.1021/acs.jmedchem.6c02429
Vancouver
Ranjit A, Tenora L, Huang M, Wu Y, Thomas AG, Lee CB, et al. Next-Generation Neutral Sphingomyelinase-2 Inhibitors with Improved Solubility, Pharmacokinetics, and Efficacy in a Tau Propagation Model. Journal of Medicinal Chemistry. 2026;69(21):26452-26468. doi:10.1021/acs.jmedchem.6c02429
BibTeX
@article{Ranjit2026,
author = {Ranjit, Arina and Tenora, Lukáš and Huang, Meixiang and Wu, Ying and Thomas, Ajit G and Lee, Chae Bin and Alt, Jesse and Zhang, Ruoning and Maragakis, Robert M and Zheng, Yuxin and Su, Yu and Pietri, Peter and Jung, Taeyoon and Slusher, Barbara S and Rais, Rana},
title = {Next-Generation Neutral Sphingomyelinase-2 Inhibitors with Improved Solubility, Pharmacokinetics, and Efficacy in a Tau Propagation Model},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {21},
pages = {26452--26468},
doi = {10.1021/acs.jmedchem.6c02429}
}
EUVIMED